Loading…
Impact of combined propranolol and oxytocin on the process and outcomes of labor: a meta-analysis of randomized controlled trials
Purpose To systematically review the impact of propranolol combined with oxytocin on the process and outcomes of labor. Methods A comprehensive literature search was performed across multiple databases, including China National Knowledge Infrastructure (CNKI), VIP, Wanfang, China Biomedical Literatu...
Saved in:
Published in: | European journal of clinical pharmacology 2024-06, Vol.80 (6), p.901-910 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose
To systematically review the impact of propranolol combined with oxytocin on the process and outcomes of labor.
Methods
A comprehensive literature search was performed across multiple databases, including China National Knowledge Infrastructure (CNKI), VIP, Wanfang, China Biomedical Literature Database, PubMed, Embase, and the Cochrane Library. All publicly published randomized controlled trials (RCTs) of propranolol combined with oxytocin compared to the use of oxytocin alone in labor were collected. After screening the literature and extracting data, the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 recommended bias risk assessment tool was used to assess the quality of the included studies. A meta-analysis was conducted using RevMan 5.3 software, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to rate the quality of evidence for outcome measures.
Results
Meta-analysis results showed that the group receiving propranolol combined with oxytocin was more capable of reducing the cesarean section rate (eight studies, 815 women, RR = 0.67, 95% CI (0.53, 0.86),
P
= 0.001) and shortening the duration of the latent phase (two studies, 206 women, MD = − 1.20, 95% CI (− 1.97, − 0.43),
P
= 0.002) and the duration of the active phase on day 1 (two studies, 296 women, MD = − 0.69, 95% CI (− 0.83, − 0.54),
P
|
---|---|
ISSN: | 0031-6970 1432-1041 |
DOI: | 10.1007/s00228-024-03659-9 |